Oncomedics

Oncomedics is a biotechnology company focused on personalizing cancer treatments through the development of in vitro diagnostic medical devices. Founded in 2006 by Dr. Christophe Lautrette and Dr. Stéphanie Giraud, the company operates its own laboratory and production facility in Limoges, France. Both founders possess strong backgrounds in Biology-Health from the University of Limoges; Dr. Lautrette drove the initial technical development of the company's core project, while Dr. Giraud's research has consistently centered on oncology and the mechanisms of tumor cells.

The company's core product is the Oncogramme®, a diagnostic test that functions similarly to an antibiogram. This functional test involves culturing a patient's own tumor cells and exposing them to various therapeutic molecules to determine which treatments or combinations are most effective at killing the cancer cells. The primary goal is to provide decision support for medical practitioners, including surgeons, pathologists, and oncologists, enabling them to select the most suitable and effective therapies for their patients. Initially targeting metastatic colorectal cancer, Oncomedics has plans to expand the Oncogramme®'s application to other cancers such as breast and ovarian cancer.

Oncomedics' business model is business-to-business, serving clients such as pharmaceutical companies, biotechnology firms, clinical research organizations, hospitals, and public research centers. Revenue is generated through direct sales of its predictive testing services. The company has established numerous collaborations with clinical centers, academic laboratories, and pharmaceutical industries. In 2022, Oncomedics was integrated into the CliniSciences Group, a move intended to support its growth and the development of the Oncogramme®. The company has received funding from investors including Limousin Participations, Siparex, and Aquiti Gestion, and was awarded a grant from the France 2030 plan to industrialize the production of reagents for the Oncogramme®.

Keywords: personalized cancer treatment, in vitro diagnostics, oncology, Oncogramme, functional cancer test, tumor cell culture, chemotherapy sensitivity, colorectal cancer, diagnostic medical device, biotechnology, personalized medicine, cancer therapy selection, predictive testing, Limoges, CliniSciences Group, Christophe Lautrette, Stéphanie Giraud, anti-tumor agents, patient-derived cells, treatment efficacy